Melvin Cheitlin

University of California at San Francisco, School of Medicine, United States of America

Melvin Cheitlin has been Emeritus Professor of Medicine at UCSF since 1997.

His research interests include cardiovascular involvement in AIDS, valvular heart disease, and severe tricuspid regurgitation

Throughout his career, Professor Cheitlin has received many awards for his outstanding achievements. He was, for example, awarded the title "Master of the American College of Cardiology" (MACC) in 1998 and Distinguished Fellow of the Society of Geriatric Cardiology. In 1999, he received the Special Recognition Award by the Laennec Society of the AHA Council on Clinical Cardiology. And in 2004, he received the Cardiology Faculty Special Award by Division of Cardiology at UCSF.

Any competing interests declared are displayed with individual evaluations.

Faculty Member: Cardiovascular Disorders > Geriatric Cardiology (since 19 September 2007)

All recent recommendations

• 6.0
  Recommendation of low-salt diet and short-term outcomes in heart failure with preserved systolic function.
  Recommended by Melvin Cheitlin
  
• 6.0
  Association between degenerative aortic valve disease and long-term exposure to cardiovascular risk factors: results of the longitudinal population-based KORA/MONICA survey.
  Recommended by Melvin Cheitlin
  
• 6.0
  Closure of atrial septal defect with the Amplatzer septal occluder in adults.
  Recommended by Melvin Cheitlin
  
• 8.2
  A randomized trial of therapies for type 2 diabetes and coronary artery disease.
  Recommended by HMJ Krans, John Ambrose, Melvin Cheitlin
  
• 4.8
  BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial.
  Recommended by Jerome Fleg, Melvin Cheitlin
  
• 6.0
  Clinical predictors of cardiac syncope at initial evaluation in patients referred urgently to a general hospital: the EGSYS score.
  Recommended by Melvin Cheitlin
  
• 9.9
  Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome.
  Recommended by Gregory Lip with Girish Dwivedi, Marrick Kukin with Catherine Weinberg , Melvin Cheitlin, John Augoustides with Prakash Patel
  
• 9.0
  Reduced ejection fraction, sudden cardiac death, and heart failure death in the mode selection trial (MOST): implications for device selection in elderly patients with sinus node disease.
  Recommended by Melvin Cheitlin
  
• 3.0
  Age and double product (systolic blood pressure x heart rate) reserve-adjusted modification of the Duke Treadmill Score nomogram in men.
  Recommended by Melvin Cheitlin
  
• 3.0
  Chronic atrial fibrillation: Incidence, prevalence, and prediction of stroke using the Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack (CHADS2) risk stratification scheme.
  Recommended by Melvin Cheitlin
  
• 6.6
  Prognostic importance of defibrillator shocks in patients with heart failure.
  Recommended by Hector Ventura, Brian Olshansky with Rakesh Gopinathannair, Melvin Cheitlin
  
• 10.0
  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
  Recommended by Melvin Cheitlin, Seth Field with Priya Shah, Judy Kersten with Nicole Lohr, Conrado Estol, Philipp M Lepper with Maximilian von Eynatten
  
• 3.0
  Decreasing body temperature predicts early rehospitalization in congestive heart failure.
  Recommended by Melvin Cheitlin
  
• 6.6
  Rosuvastatin in older patients with systolic heart failure.
  Recommended by Jerome Fleg, Wilbert Aronow, Melvin Cheitlin
  
• 3.2
  Effect of statins, angiotensin-converting enzyme inhibitors, and beta blockers on survival in patients >or=65 years of age with heart failure and preserved left ventricular systolic function.
  Recommended by Mariell Jessup, Melvin Cheitlin
  
• 6.0
  Management of prosthetic valve infective endocarditis.
  Recommended by Melvin Cheitlin
  
• 3.0
  CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study.
  Recommended by Melvin Cheitlin
  
• 9.0
  Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
  Recommended by Melvin Cheitlin
  
• 3.0
  Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs).
  Recommended by Melvin Cheitlin
  
• 9.0
  Antecedent blood pressure, body mass index, and the risk of incident heart failure in later life.
  Recommended by Melvin Cheitlin
  
• 9.0
  Protective effect of long-term angiotensin II inhibition.
  Recommended by Melvin Cheitlin
  
• 3.0
  Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials.
  Recommended by Melvin Cheitlin
  
• 8.0
  Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group.
  Recommended by Melvin Cheitlin, Ralph Corey